New Board Members Join PolyTherics
News Aug 24, 2012
PolyTherics Limited has announced that Dr Anker Lundemose and Nigel Pitchford have joined its Board.
Dr Lundemose is co-founder of several companies including Symphogen A/S and Santaris A/S and was co-founder and CEO of Prosidion Ltd, a UK subsidiary of OSI Pharmaceuticals Inc. He is also a former managing director of OSI’s venture capital arm.
Dr Lundemose is medically qualified and has a PhD in molecular biology. He started his industry career in research with Novo Nordisk before moving into business development and has an international reputation in R&D productivity and for executing high profile licensing and M&A deals.
Nigel Pitchford is Managing Director of Healthcare Investments at Imperial Innovations Group plc. Nigel brings many years of experience as a venture capital investor to the PolyTherics board, drawn from his time with 3i and DFJ Esprit.
Ken Cunningham, Chairman of PolyTherics, welcomes Nigel and Anker to the board, saying, “As PolyTherics makes significant commercial progress with its expanded technology offering and its increasingly successful licensing strategy, these valuable additions to the Board set up the company for its next phase of development.”
Bacterial Control Mechanism for Adjusting to Changing ConditionsNews
A fundamental prerequisite for life on earth is the ability of living organisms to adapt to changing environmental conditions. Physicists have now determined that the regulation mechanisms used by bacteria to adapt to different environments are based on a global control process that can be described in a single equation.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon TherapeuticsNews
Companies have entered into agreement for the development and manufacturing of three TriTAC molecules for the treatment of cancers.READ MORE